- Among patients with stage III endometrial cancer confined to the pelvis, adjuvant chemoradiotherapy (CRT) tops radiotherapy (RT) for OS in grade 3 disease.
- Grade 3 disease was significantly associated with worse outcomes.
Why this matters
- Optimal adjuvant management remains unclear in this population.
- 144 patients diagnosed with stage IIIA, B, or C1 endometrial cancer who underwent surgical resection followed by adjuvant RT, CRT, chemotherapy, or no further treatment.
- Funding: None disclosed.
- Median follow-up, 61 months.
- Patients treated with RT alone vs CRT showed similar:
- 5-year OS: 67% vs 61% (P=.546).
- 5-year DFS: 67% vs 51%.
- 5-year disease-specific survival (DSS): 76% vs 65%.
- Grade 3 disease showed significant association with worse OS (HR, 6.01; P=.001), DFS (HR, 3.16; P=.03), and DSS (HR, 3.77; P=.02).
- Among patients with grade 3 disease (n=49), the 5-year OS rate was significantly higher with adjuvant CRT vs RT (56% vs 42%; P=.007).
- Acute grade 3-4 toxicities were diagnosed in 6% and 35% of patients treated with adjuvant RT and CRT, respectively.
- Retrospective design.